TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105

TRACON Pharmaceuticals (NASDAQ:TCON), announced that positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma were presented in a poster presentation at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.
As quoted in the press release:

Charles Theuer, M.D., Ph.D., President and CEO of TRACON said, “Importantly, the initial data from the current trial are consistent with the 33% partial response rate by RECIST 1.1 reported in the completed Phase 1/2 study published by the National Cancer Institute in 2017. We expect to complete enrollment of the current multicenter study by the end of 2018, and will discuss a potential registration-enabling study of the combination of TRC105 and Nexavar in HCC with regulatory authorities shortly thereafter.”

Click here to read the full press release.